Current status of hepatocellular carcinoma in Japan

Chinese Clinical Oncology

Volumn 2, Issue 4, 2013, Pages

  Ikeda, Masafumi ^a   Mitsunaga, Shuichi ^a   Shimizu, Satoshi ^a   Ohno, Izumi ^a   Takahashi, Hideaki ^a   Okuyama, Hiroyuki ^a   Kuwahara, Akiko ^a   Okusaka, Takuji ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Hepatic arterial infusion chemotherapy (haic); Hepatocellular carcinoma (HCC); Lenvatinib; Liver transplantation; Local ablative therapy; Orantinib; Peretinoin; S 1; Surgical resection; Systemic chemotherapy; Transcatheter arterial chemoembolization (tace)

Indexed keywords

EID: 84959868456     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.3978/j.issn.2304-3865.2013.09.01     Document Type: Review

References (37)

1. Matsuda A, Matsuda T, Shibata A, et al. Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2013;43:328-36.
2. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available online: http://globocan.iarc.fr, accessed on day/month/year
3. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127:S17-26.
4. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010;53:39-43.
5. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131:174-81.
6. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
7. Ikai I, Kudo M, Arii S, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010;40:1043-59.
8. The Japan Society of Hepatology. Evidence-based clinical practice guidelines for hepatocellular carcinoma, revised version (in Japanese). Tokyo: Kanehara, 2009.
9. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51.
10. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-64.
11. Kudo M, Izumi N, Kokudo N, et al. Improved survival in patients with HCC over 30 years in Japan: analysis of nationwide prospective registry of 148,161 patients. J Clin Oncol 2011;29:abstr 4054.
12. Liver transplantation in Japan-registry by the Japanese Liver Transplantation Society-(in Japanese)-registry by the Japanese Liver Transplantation Society-. Ishoku 2011;46:524-36.
13. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
14. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
15. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
16. Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011;54:2055-63.
17. Chiu J, Tang YF, Yao TJ, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012;118:5293-301.
18. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-65.
19. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011;47:2117-27.
20. Kudo M, Ye SL, Venook A, et al. Second interim analysis of GIDEON (Global Investigation of therapeutic DEcisions in unresectable HCC and Of its treatment with sorafeNib): multiregional variation in patient characteristics, previous treatment history, and sorafenib use. The 62nd Annual Meeting of AASLD, 2011:abstr 2183.
21. Iwasa S, Ikeda M, Okusaka T, et al. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol 2011;41:770-5.
22. Yoshikawa M, Ono N, Yodono H, et al. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008;38:474-83.
23. Court WS, Order SE, Siegel JA, et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002;20:613-25.
24. Furuse J, Ikeda M, Okusaka T, et al. A phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced HCC with portal vein tumor thrombosis. J Clin Oncol 2008;26:abstr 15556.
25. Park JY, Ahn SH, Yoon YJ, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-37.
26. Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010;78 Suppl 1:148-53.
27. Kim BK, Park JY, Choi HJ, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011;137:659-67.
28. Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res 2012;42:340-8.
29. Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005;93:557-64.
30. Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006;106:1990-7.
31. Uka K, Aikata H, Takaki S, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007;42:845-53.
32. Nagano H, Wada H, Kobayashi S, et al. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011;80:63-9.
33. Monden M, Sakon M, Sakata Y, et al. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: a multicenter, randomized, phase II study. Hepatol Res 2012;42:150-65.
34. Okita K, Kumada K, Ikeda K, et al. Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced HCC(HCC): Initial assessment of response rate. J Clin Oncol 2012;30:abstr 320.
35. Arai Y, Inaba Y, Yamamoto T, et al. A randomized phase II study of TSU-68 in patients (pts) with HCC (HCC) treated by transarterial chemoembolization (TACE). J Clin Oncol 2010;28:abstr 4030.
36. Furuse J, Okusaka T, Kaneko S, et al. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci 2010;101:2606-11.
37. Okita K, Matsui O, Kumada H, et al. Effect of peretinoin on recurrence of HCC (HCC): Results of a phase II/III randomized placebo-controlled trial. J Clin Oncol 2010;28:abstr 4024.